EU committee votes through laws on counterfeits and pharmacovigilance
This article was originally published in Scrip
New EU laws on counterfeit medicines and pharmacovigilance edged a step closer to approval today after a European Parliament committee adopted the draft legislation in first reading with a firm emphasis on protecting public health. The proposals are part of the "pharmaceutical package" drawn up by the European Commission.
You may also be interested in...
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.